Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

Yafit Segman, Elena Ribakovsky, Abraham Avigdor, Yair Goldhecht, Vladimir Vainstein, Neta Goldschmidt, Shimrit Harlev, Netanel Horwitz, Odit Gutwein, Ronit Gurion, Gilad Itchaki, Uri Abadi, Anatoly Nemets, Orit Sofer, Miri Zektser, Tamar Tadmor, Nagib Dally, Kalman Filanovsky, Merav Leiba, Nadav SaridNoam Benyamini, Yair Herishanu, Ron Ram, Chava Perry, Irit Avivi

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with de-novo DLBCL and 16 with transformed lymphoma, treated with polatuzumab-based regimen in 14 Israeli centers between June 2018 and November 2019, were included. Median age was 66.1 years (60.4–78.8) and median number of prior lines was 3 (2–7). The overall response rate was 61% (n = 29), including 40% complete responses (n = 19) and 21% (n = 10) partial responses. The median overall survival and progression-free survival were 8.3 months and 5.6 months, respectively. An ECOG PS ≥2 predicted a decreased overall survival (p = 0.045). Primary refractory vs relapsed disease (p = 0.005) and transformed vs de-novo DLBCL (p = 0.039) were associated with shorter PFS (p = 0.027). Our data show that polatuzumab-based regimen is an effective and tolerable treatment in relapsed/refractory DLBCL.

Original languageEnglish
Pages (from-to)118-124
Number of pages7
JournalLeukemia and Lymphoma
Volume62
Issue number1
DOIs
StatePublished - 1 Jan 2021
Externally publishedYes

Keywords

  • Lymphoma and Hodgkin disease
  • immunotherapeutic approaches
  • relapsed refractory DLBCL

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience'. Together they form a unique fingerprint.

Cite this